Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is a stable analog of the prostaglandin epoprostenol (prostacyclin) with pharmacokinetics and vasodilator and antiplatelet properties similar to those of epoprostenol.
Used in peripheral vascular disorders and pulmonary hypertension.
Administration by intravenous infusion or by inhalation.
At the date of the last update we did not find any published data on its excretion in breast milk.
Its acid pKa and large volume of distribution, as well as its very fast elimination half-life (T½ of 15 - 30 minutes) make it unlikely to pass into breast milk in significant amount.
Its low oral bioavailability (Kirsten 1998) makes it difficult for the infant to pass into plasma from ingested breast milk.
No problems were reported in a newborn breastfed by a mother treated with iloprost (Mirdamadi 2016).
It is a medication that is used in newborns, including premature (Verma 2021, Eifinger 2008).
See below the information of this related product: